G8

G8 is a South Korean biotechnology company focused on the discovery and development of innovative therapeutics targeting G protein-coupled receptors (GPCRs). The company leverages its proprietary G8-GPCR platform, which integrates structural biology and protein engineering to address the historical difficulties of targeting GPCRs, such as low expression and instability. G8's pipeline includes monoclonal antibodies and small molecules designed for indications in oncology, metabolic diseases, and inflammatory conditions. By focusing on previously "undruggable" GPCR targets, the company aims to deliver breakthrough treatments for patients with limited therapeutic options. The leadership team brings extensive experience from major pharmaceutical firms, positioning G8 as a specialized player in the GPCR drug discovery space.